Abstracts tagged "Juvenile idiopathic arthritis"

Abstract Number: 0740 • ACR Convergence 2022
Real-World Demographics, Clinical Characteristics, and Treatment Patterns of Patients Treated with Emapalumab for Secondary Hemophagocytic Lymphohistiocytosis in the United States: The REAL-HLH Study
Carl Allen¹, Shanmuganathan Chandrakasan², Michael Jordan³, Jennifer Leiding⁴, Abiola Oladapo⁵, Priti Pednekar⁶, Kelly Walkovich⁷ and John Yee⁸, ¹Baylor College of Medicine, Houston, TX, ²Emory University School of Medicine, Atlanta, GA, ³University of Cincinnati, Cincinnati, OH, ⁴Johns Hopkins University, Baltimore, MD, ⁵Swedish Orphan Biovitrum AB, Boston, MA, ⁶PRECISIONheor, Los Angeles, CA, ⁷University of Michigan Health, Ann Arbor, MI, ⁸Sobi - North America, Waltham, MA
Background/Purpose: Hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening, hyperinflammatory syndrome caused by overproduction of proinflammatory cytokines, e.g., interferon gamma (IFNγ). Secondary HLH (sHLH), a subtype…
Abstract Number: 0868 • ACR Convergence 2022
Spondyloarthritis and Neonatal Factors Affecting the Gut Microbiome
Joy Um¹, Douglas Einstadter², Myung-Yong Um³ and Maria Antonelli¹, ¹Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH, ²Center for Health Care Research and Policy, Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH, ³Department of Social Welfare, Sungkyunkwan University, Seoul, Republic of Korea
Background/Purpose: Spondyloarthritis (SpA) consists of clinically and genetically related but phenotypically distinct disorders, including ankylosing spondylitis, enteropathic arthritis, psoriatic arthritis, reactive arthritis, and enthesitis-related arthritis…
Abstract Number: 1939 • ACR Convergence 2022
Safety and Humoral Response Following the Second and Third Doses of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents with Juvenile-onset Autoimmune Inflammatory Rheumatic Diseases
Merav Heshin-Bekenstein¹, amit ziv², NATASA TOPLAK³, Adi Miller Barmak⁴, Siman Lazauskas⁵, Danielle Kadishevich⁶, Efrat Ben Nun⁶, Esther Saiag⁷, Yonatan Butbul Aviel⁴, Gabi Shefer⁷, Sara Pel⁸, Ori Elkayam⁷ and Yosef Uziel⁹, ¹Dana Dwek Children's Hospital, Tel Aviv Medical Center Israel, Binyamina, Israel, ²Meir Hospital, Kfar Saba, Israel, ³University of Ljubljana, Ljubljana, Slovenia, ⁴Rambam Medical Center, Haifa, Israel, ⁵Tel Aviv Medical Center, Tel Aviv, Israel, ⁶Meir Medical Center, Kfar Saba, Israel, ⁷Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁸Department of Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel, ⁹Meir Medical Center, Kfar Saba; Sackler School of Medicine, Tel Aviv University, Kfar Saba, Israel
Background/Purpose: Long-term data on the safety and dynamics of the immune response to the BNT162b2 mRNA COVID-19 vaccine in adolescents with juvenile-onset autoimmune inflammatory rheumatic…
Abstract Number: 0808 • ACR Convergence 2022
Transitional Care in Juvenile Idiopathic Arthritis: Timing, Prevalence of Subtypes and Treatment Profile in a Spanish Tertiary Hospital
Cristobal Pavez Perales¹, Alba Torrat Novés², José Ivorra Cortés¹, Samuel Leal Rodriguez¹, Anderson V Huaylla Quispe³, Carmen Riesco Bárcena², Laura Mas Sanchez¹, Pablo Muñoz Martinez⁴, Elena Grau García¹, Elvira Vicens Bernabeu¹, José Eloy Oller Rodrígez¹, Francisco Miguel Ortiz Sanjuan⁵, Isabel Martínez-Cordellat¹, Rosa Negueroles Albuixech¹, Berta Lopez Montecinos⁶, Carmen Nájera Herranz¹, Inés Cánovas Olmos¹, Daniel Ramos Castro¹, Inmaculada Calvo Penades⁷, Luis González Puig⁸ and José andrés Román ivorra⁹, ¹Rheumatology Department. Hospital Universitario y Politécnico La Fe, València, Spain, ²Rheumatology Department. Hospital Universitario y Politécnico La Fe, València, ³Rheumatology Department. Hospital Universitario y Politécnico La Fe, València, Comunidad Valenciana, Spain, ⁴Rheumatology Department. Hospital Universitario y Politécnico La Fe, Sagunto, Spain, ⁵Rheumatology Department. Hospital Universitario y Politécnico La Fe, Spain, Spain, ⁶Pediatric Rheumatology Unit. Hospital Universitario y Politécnico La Fe, València, Comunidad Valenciana, Spain, ⁷Pediatric Rheumatology Unit, Hospital Universitario y Politécnico La Fe, València, Spain, ⁸Rheumatology Department. Hospital Universitario y Politécnico La Fe, Torrente, Valencia, Spain, ⁹Hospital Universitari i Politécnic la Fe, València, Spain
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the leading cause of chronic inflammatory rheumatic disease in children. It's classified into subtypes with different relative prevalences depending…
Abstract Number: 0870 • ACR Convergence 2022
Knee Acoustic Emissions as a Noninvasive Biomarker of Articular Health in Juvenile Idiopathic Arthritis
Sevda Gharehbaghi¹, Emily Moise¹, Priya Brito², Lori Ponder³, Omer Inan¹ and Sampath Prahalad⁴, ¹Georgia Institute of Technology, Atlanta, GA, ²Emory University, Atlanta, GA, ³Children's Healthcare of Atlanta, Atlanta, GA, ⁴Emory + Children's Pediatric Institute, Atlanta, GA
Background/Purpose: Juvenile idiopathic arthritis (JIA) refers to all forms of autoimmune arthritis in children with undetermined etiology, and thus it is the most prevalent chronic…
Abstract Number: 1943 • ACR Convergence 2022
Prevalence and Evolution of Undifferentiated Periodic Fever Syndromes in an Academic Pediatric Rheumatology Practice
Jacob Anderson¹, Catherine Bingham², Lisabeth Scalzi³, Natalya Gaffney⁴, Kimberly Hays⁵, Brandt Groh² and Timothy Hahn², ¹Phoenix Children's Hospital, Phoenix, AZ, ²Penn State Children's Hospital, Hershey, PA, ³Penn State Health, Hummelstown, PA, ⁴Self-Employed, Carlisle, PA, ⁵Penn State Health, Hershey, PA
Background/Purpose: Periodic Fever Syndromes (PFS) are common referrals to pediatric rheumatology clinics. While the syndrome of Periodic Fevers, Aphthous stomatitis, Pharyngitis, and Adenitis (PFAPA) is…
Abstract Number: 0850 • ACR Convergence 2022
Outcomes of Patients with Juvenile Idiopathic Arthritis Following Failure of Initial Tumor Necrosis Factor Inhibitor Medication in the Childhood Arthritis and Rheumatology Research Alliance Registry
Melissa Mannion¹, Shahla Amin², Stephen Balevic³, Colleen Correll⁴, Timothy Beukelman¹ and , for the CARRA Registry Investigators⁵, ¹University of Alabama at Birmingham, Birmingham, AL, ²Childhood Arthritis and Rheumatology Research Alliance, Washington, DC, ³Duke University, Durham, NC, ⁴University of Minnesota, Minneapolis, MN, ⁵CARRA, Washington, DC
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are the most commonly used first biologics to treat juvenile idiopathic arthritis (JIA), but it is unknown what subsequent…
Abstract Number: 0873 • ACR Convergence 2022
Celiac-Associated Arthritis: Clinical Features, Treatment, and Outcomes
Ana Luiza Altaffer¹ and Pamela Weiss², ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Children's Hospital of Philadelphia, Glen Mills, PA
Background/Purpose: Although arthritis is recognized as one of the extra-intestinal manifestations of celiac disease, little is known about the clinical course and outcomes of celiac-associated…
Abstract Number: 1944 • ACR Convergence 2022
Description and Delays in Care in the Bridge to Adult Care from Childhood for Young Adults with Rheumatic Disease (BACC YARD) Program, a Pediatric-to-Adult Rheumatology Transition Program
John Bridges¹, Livie Huie², Amanda Alexander³, Randy Cron², Maria Danila², Victoria Gennaro⁴, Laura Hughes², Bailey Lipham⁵, Linda McAllister⁶, Matthew Mullen⁷, Annelle Reed⁴, Daniel Reiff², Carolyn Smith⁴, Emily Smitherman², Matthew Stoll², Peter Weiser² and Melissa Mannion², ¹University of Alabama at Birmingham/Children's of Alabama, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Homewood, AL, ⁴Children's of Alabama, Birmingham, AL, ⁵University of Alabama Medical School, Birmingham, AL, ⁶Children's of Alabama, Trussville, AL, ⁷University of Alabama-Birmingham, Vestavia Hills, AL
Background/Purpose: Children with chronic rheumatic conditions age and require transfer to adult rheumatologists for continued care. The transition period from pediatric to adult-oriented care is…
Abstract Number: 0851 • ACR Convergence 2022
Responsiveness of Patient-Reported Physical Function Measures in Juvenile Arthritis
Alysha Taxter¹, Laura Schanberg², Marc Natter³ and for the CARRA Registry investigators⁴, ¹Nationwide Children's Hospital, Columbus, OH, ²Duke University Medical Center, Durham, NC, ³Boston Children's Hospital, Boston, MA, ⁴CARRA, Washington, DC
Background/Purpose: The ACR Pediatric Criteria (ACR Pedi) contains a core set of outcome variables, including a measure of functional ability, to evaluate improvement over time…
Abstract Number: 0874 • ACR Convergence 2022
A Tale of Many Canadas: Associations of Ethnicity with Juvenile Idiopathic Arthritis Categories and Disease Severity at Presentation in a Multicultural Universal Healthcare Setting: Results from ReACCh-Out
Stephanie Wong¹, Lori Tucker², Kristin Houghton³, David Cabral⁴, Mercedes Chan², Ross Petty³, Andrea Human², Kimberly Morishita³, Rae Yeung⁵, Kiem Oen⁶, Ciaran Duffy⁷, Roberta Berard⁸, Gaelle Chedeville⁹, Thomas Loughin¹⁰, Matthew Berkowitz¹⁰ and Jaime Guzman¹¹, ¹University of British Columbia, Vancouver, BC, Canada, ²British Columbia Children's Hospital, Vancouver, BC, Canada, ³University of British Columbia - Vancouver, Vancouver, BC, Canada, ⁴BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ⁵The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ⁶University of Manitoba, Toronto, ON, Canada, ⁷University of Ottawa, Ottawa, ON, Canada, ⁸London Health Sciences Centre, London, ON, Canada, ⁹McGill University, Montréal, QC, Canada, ¹⁰Simon Fraser University, Vancouver, BC, Canada, ¹¹University of British Columbia and BC Children's Hospital, Vancouver, BC, Canada
Background/Purpose: The distribution of Juvenile Idiopathic Arthritis (JIA) categories and disease severity at presentation vary across countries, however it is unclear how much of this…
Abstract Number: 2209 • ACR Convergence 2022
Efficacy of Secukinumab in Enthesitis-related Arthritis and Juvenile Psoriatic Arthritis Subtypes of Juvenile Idiopathic Arthritis: Results from a Randomized, Phase 3 Study
Hermine Brunner¹, Elena Chertok², Joke Dehoorne³, Gerd Horneff⁴, Tilmann Kallinich⁵, Ingrid Louw⁶, Maria Alessio⁷, Sandrine Compeyrot-Lacassagne⁸, Bernard Lauwerys⁹, Neil Martin¹⁰, Katherine Marzan¹¹, W Patrick Knibbe¹², Ruvie Martin¹³, Xuan Zhu¹⁴, sarah whelan¹⁵, Luminita Pricop¹⁶, Daniel Lovell¹⁷, Alberto Martini¹⁸ and Nicola Ruperto¹⁹, ¹Division of Rheumatology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Department of Pediatrics, Cincinnati, OH, ²Voronezh State Medical University, Voronezh, Russia, ³University Hospital Gent, Gent, Belgium, ⁴Pediatrics, Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany, ⁵Charité - Universitätsmedizin Berlin, Nuremberg, Germany, ⁶Panaroma Medical Centre, Cape Town, South Africa, ⁷Policlinico Federico II di Napoli, Napoli, Italy, ⁸Great Ormond Street Hospital for Children, London, United Kingdom, ⁹Cliniques Universitaires Saint-Luc, Brussels, Belgium, ¹⁰Royal Hospital for Children, Glasgow, Scotland, United Kingdom, ¹¹Children's Hospital Los Angeles, Los Angeles, CA, ¹²St. Luke's Hospital System, Meridian, ID, ¹³Novartis Pharmaceutical Corporation, East Hanover, NJ, ¹⁴Novartis Pharmaceuticals Corporation, Basking Ridge, NJ, ¹⁵Novartis Ireland Ltd, Crumlin, Dublin, Ireland, ¹⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁷Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁸Istituto Giannina Gaslini, Genova, Italy, ¹⁹IRCCS Istituto Giannina Gaslini; PRINTO, Clinica Pediatrica e Reumatologia, Genova, Italy
Background/Purpose: Juvenile idiopathic arthritis (JIA) categories of enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) represent pediatric counterparts of adult non-radiographic axial spondyloarthritis and psoriatic…
Abstract Number: 0853 • ACR Convergence 2022
Reliability of MRI Lesions Comprising the Preliminary OMERACT Juvenile Idiopathic Arthritis MRI Score (OMERACT JAMRI-SIJ): What Is the Impact of Systematic Reader Calibration?
Walter P Maksymowych¹, Nisha Varma², Arthur Meyers³, Jennifer Stimec⁴, Nikolay Tzaribachev⁵, Jonathan Akikusa⁶, Tarimobo Otobo⁴, Marion von Rossum⁷, Andrea Doria⁴ and Nele Herregods⁸, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Department of Paediatric Radiology, The Royal Children's Hospital Melbourne, Melbourne, Australia, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Department of Diagnostic Imaging, SickKids, University of Toronto, Toronto, ON, Canada, ⁵PRI Research Institute, Bad Bramstedt, Germany, ⁶Rheumatology Service, Royal Children’s Hospital, Melbourne, Melbourne, Australia, ⁷Emma Children’s Hospital, Dept Pediatrics, Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁸Ghent University Hospital, Ghent, Belgium
Background/Purpose: The evaluation of the sacroiliac joints (SIJ) in children with Juvenile Idiopathic Arthritis (JIA) increasingly relies on the use of MRI since radiography is…
Abstract Number: 0875 • ACR Convergence 2022
Predictive Biomarkers of Tofacitinib Response and Disease Activity in Juvenile Idiopathic Arthritis Subtypes: A Longitudinal Study
Ekemini Ogbu¹, Sherry Thornton², Alyssa Sproles², Alexei Grom³, Sanjeev Dhakal⁴, Bin Huang⁵ and Hermine Brunner⁶, ¹Cincinnati Children's Hospital Medical Center, Atlanta, GA, ²Cincinnati Children's Hospital, Cincinnati, OH, ³Divisions of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Cincinnati Children's Hospital Medical Center, Cinciannati, OH, ⁶Division of Rheumatology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Department of Pediatrics, Cincinnati, OH
Background/Purpose: Tofacitinib has been shown to improve disease activity of several subtypes of Juvenile Idiopathic Arthritis (JIA). No known biomarkers to date predict JIA improvement…
Abstract Number: 2210 • ACR Convergence 2022
Baricitinib in Juvenile Idiopathic Arthritis: A Phase 3, Double-Blind, Placebo-Controlled, Withdrawal, Efficacy and Safety Study
Athimalaipet Ramanan¹, Pierre Quartier Dit Maire², Nami Okamoto³, Gabriella Meszaros⁴, Joana Araujo⁴, Zhongkai Wang⁴, Ran Liao⁴, Brenda Crowe⁴, Xin Zhang⁴, Rodney Decker⁴, Stuart Keller⁴, Hermine Brunner⁵ and Nicola Ruperto⁶, ¹Bristol Royal Hospital for Children, Bristol, United Kingdom, ²Necker hospital, Paris Cedex 15, France, ³Osaka Medical College, Takatsuki-city, Japan, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Division of Rheumatology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Department of Pediatrics, Cincinnati, OH, ⁶IRCCS Istituto Giannina Gaslini; PRINTO, Clinica Pediatrica e Reumatologia, Genova, Italy
Background/Purpose: Baricitinib is a JAK1/2 selective inhibitor approved for the treatment of rheumatoid arthritis. Juvenile idiopathic arthritis (JIA) is a group of diseases characterized by…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].